The Hindu National
์ค๋ ์ฑํฅ
์ ์น
Focus on creating โMessisโ in Kerala, not just bringing Messi: O.J. Janeesh
Sports policy, grassroots infrastructure and youth engagement to be prioritised, says Minister
๐ฎ๐ณ ์ธ๋ ยท "CREATING" ยท ์ด 14๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
50.0
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 6,237๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 50.0(๊ท ํ)์ ๋๋ค. ๊ธ์ 0๊ฑด(0.0%)ยท์ค๋ฆฝ 6,237๊ฑด(100.0%)ยท๋ถ์ 0๊ฑด(0.0%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 0.0(์ค๋ ๊ท ํ)์ ๋๋ค.
Sports policy, grassroots infrastructure and youth engagement to be prioritised, says Minister
Skywatchers are in for a treat as Venus and Jupiter align closely on June 9, appearing almost side-by-side in the western sky after sunset. This celestial spectacle, visible to the naked eye, will also feature Mercury from June 11, creating a rare three-planet parade in the constellation Gemini. Binoculars will enhance the view of this stunning astronomical event.
AIMIM chief Asaduddin Owaisi criticizes the Election Commission's voter list revision, fearing it could disenfranchise Muslims, women, migrants, and the poor, creating "excluded Indians." He alleges the exercise, which has already removed millions, is a precursor to identifying illegal immigrants. The Supreme Court, however, has upheld the EC's authority to ensure accurate electoral rolls.
Ranveer Singh's Dhurandhar franchise has rewritten the box-office record books, with Dhurandhar and Dhurandhar: Revenge together earning more than Rs 3,000 crore worldwide. But according to producer Jyoti Deshpande, the journey to creating one of Indian cinema's biggest franchises was far from straightforward. She revealed how the makers navigated ballooning budgets, reimagined the project as a two-part saga midway through production, and adopted a unique risk-sharing model involving lead star Ranveer Singh and director Aditya Dhar.
New Delhi: Beverages major PepsiCo on Tuesday announced the launch of its premium energy drinks brand 'Adrenaline Rush' in the Indian market, strengthening its presence in the category, which has seen strong growth in recent years.Pepsico, a leading player in the energy drinks with its brand Sting, now enters the mass-premium segment with 'Adrenaline Rush', creating a portfolio that spans from Rs 20 to Rs 60 price points. Adrenaline Rush is priced at Rs 60, while Sting costs Rs 20."With two variants under Sting and two variants under its premium offering, PepsiCo is broadening consumer choice while addressing a wider range of taste preferences and consumption occasions," the company said in a statement.With its two brands -- Sting and Adrenaline Rush -- PepsiCo's energy drinks portfolio will cater to a broad spectrum of consumers, seeking value propositions to those looking for a more premium, performance-led experience.Also Read: PepsiCo new packaging to carry 'No Artificial Flavours or Colours' labelCommenting on the development, PepsiCo India and South Asia, Vice President and General Manager -- Beverages, Nitin Bhandari said, "The energy drinks category in India continues to see strong growth, and we believe there is significant headroom for further expansion as consumers increasingly seek products that cater to different occasions, functional needs and aspirations."With Adrenaline Rush, PepsiCo is strengthening its energy drinks portfolio with a globally aspirational brand tailored for Gen-Z consumers, offering two differentiated variants -- Passion Rush and Classic Rush -- in a sleek premium can format to cater to the evolving preferences of today's youth.For Adrenaline Rush, PepsiCo has launched a high-energy campaign film centred on the proposition "A-Rush, A-Game On," adopting a digital-first and culture-forward approach.Also Read: PepsiCo to invest Rs 5,700 crore in India by 2030This is aimed at resonating with Gen-Z consumers through creator-led storytelling, internet culture, and social media conversations.As per a Mordor Intelligence report, the India energy drinks market size is valued at USD 0.82 billion in 2026 and is growing at a CAGR of roughly 2-6 per cent, helped by factors such as rising disposable incomes, rapid urbanisation, and an increasing need for quick-energy solutions among young working professionals.
Vice-Chancellor insists on enforcing the regulations even as concerns are raised over the move affecting admissions and creating a crisis in higher education
Every major RCB win in IPL 2026 featured a different hero. Sometimes it was Kohli. Sometimes Patidar. Sometimes Padikkal. Sometimes David. Sometimes Krunal. Sometimes Bhuvneshwar. Sometimes it was the bowlers operating as a collective unit. That was the defining characteristic of this championship side. The first IPL trophy ended one of the league's longest waits. The second confirmed something even more important. Royal Challengers Bengaluru are no longer a franchise chasing history. They may well be on their way to creating one.
The shocking sexual assault and murder of a 10-year-old girl near Sulur in Coimbatore comes as a reminder that constant vigilance and creating a safe society for women and girls should be among the top priorities for the new government in Tamil Nadu
India needs to remain watchful on the inflation front as rising fuel prices, a weakening rupee and the risk of a below-normal monsoon threaten to rekindle price pressures, the finance ministry said just days before the Reserve Bank of India's monetary policy decision.In its monthly economic review for May, the Department of Economic Affairs said the economy remains "cautiously resilient", with domestic fundamentals largely holding up despite growing global and domestic uncertainties.Also Read: RBI to hold rates in June; majority now expect hike by year-end: Poll"The confluence of elevated global energy prices, a depreciating rupee, rising upstream cost pressures and the prospect of a below-normal monsoon calls for sustained policy vigilance," the ministry said.The assessment comes ahead of the RBI's Monetary Policy Committee meeting next week, with the policy decision due on June 5. Expectations of a tighter policy stance have increased amid concerns over inflationary pressures and efforts to support the rupee, which touched a record low of nearly 97 against the US dollar earlier this month.While retail inflation remained below the RBI's 4% target in April, the ministry cautioned that wholesale price pressures have accelerated sharply, raising the risk that higher input costs could eventually feed into consumer prices.Producer inflation climbed to a more than three-and-a-half-year high in April as elevated energy prices pushed up manufacturing costs. Data from the Ministry of Commerce and Industry showed the wholesale price index rose 8.30% year-on-year, up from 3.88% in March and well above economists' expectations of 5.50%.Also Read: RBIโs currency printing cost falls 23.5% in FY26 despite rise in cash circulationThe ministry also warned that the fallout from the West Asia conflict poses a significant risk to India's inflation and external-sector outlook, particularly through disruptions to energy supplies."The duration of the Strait of Hormuz disruption remains the 'single most consequential variable for India's external and price outlook'," it said.According to the review, higher crude oil prices, tighter global financial conditions and slowing world growth are creating headwinds for the Indian economy that cannot be fully insulated from external shocks."Policy will need to remain agile across monetary, fiscal, and structural dimensions to navigate this period of compounded uncertainty, external and climatic, while keeping medium-term growth objectives firmly in view," the ministry said.
Mahindra Manulife Mutual Fund announced the launch of โMPOWER SIFโ marking its entry into SEBIโs newly notified investment product called Specialized Investment Fund and reinforcing its commitment to bringing differentiated investment solutions to investors.With MPOWER SIF, Mahindra Manulife Mutual Fund aims to address the evolving needs of investors, who are looking to complement their existing mutual funds with products that use derivatives and other tools to create different risk return outcomes.Also Read | Smallcap valuations turn favourable as correction creates fresh opportunities: Bajaj Finserv AMC The fund house aims to provide a client experience that seeks to meet the investors aspiration, whilst remaining true to the core premise of creating investment outcomes that are consistent and meaningful.โThe launch of MPOWER SIF is a significant step forward in expanding our product suite. As investors and their goals and aspirations evolve over time, there is a clear requirement for investment solutions that offer greater flexibility and use the entire range of tools available to deliver consistent outcomes. This approach is complemented by an investment team with extensive experience anchored by a sound risk management framework,โ said Anthony Heredia, MD & CEO, Mahindra Manulife Investment Management.Mahindra Manulife Mutual Fund intends to roll out a range of differentiated strategies under MPOWER SIF across equity, hybrid, and fixed income categories, aligned with regulatory guidelines and investor suitability.โMPOWER SIF gives us the flexibility to design more agile and outcome-oriented portfolios by leveraging a wider investment toolkit. This platform will enable us to combine fundamental research with tactical allocation strategies, with the objective of delivering superior risk-adjusted returns across market cycles. We believe it is well suited for investors seeking a more nuanced approach to portfolio construction,โ said Krishna Sanghavi, Chief Investment Officer - Equity, Mahindra Manulife Investment Management.Also Read | Should senior citizens continue investing in equity mutual funds after retirement? Expert explainsThe SIF category offers strategies that go beyond conventional Mutual Funds, including long-short approaches, derivatives-based strategies, and more focused portfolio construction, catering to investors seeking a different approach to meeting their investment goals.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)If you have any mutual fund queries, message on ET Mutual Funds on Facebook/Twitter. We will get it answered by our panel of experts. Do share your questions on ETMFqueries@timesinternet.in alongwith your age, risk profile, and Twitter handle.
New Delhi: Outgoing Chief of Defence Staff Gen Anil Chauhan on Saturday described his tenure as "very satisfying" as he wrapped up a three-year-and-eight-month stint at the top military post, during which he focused on bringing synergy among the three services.Lt Gen NS Raja Subramani (retd) will take charge as India's next Chief of Defence Staff (CDS) on Sunday."I had a very satisfying and excellent tenure," the outgoing CDS told reporters after he was accorded a ceremonial tri-services guard of honour.Gen Chauhan, a former Eastern Army Commander, took charge as the country's senior-most military commander in September 2022, over nine months after the first CDS General Bipin Rawat died in a helicopter crash in Tamil Nadu.As Chief of Defence Staff, Gen Chauhan played a key role in planning and implementation of Operation Sindoor along with the three service chiefs.During his tenure, he focused on ensuring tri-services synergy to enhance India's military prowess in view of the evolving regional security scenario.The Chief of Defence Staff also initiated a number of measures towards India's plan to roll out the theaterisation model by creating integrated military commands."It's a matter of great honour for me to superannuate with a tri-services guard of honour. I thank the three services and Headquarters IDS (Integrated Defence Staff) for it. With the conclusion of the guard of honour, I bid farewell to my colleagues in uniform, comrades in arms," Gen Chauhan said."I just laid the wreath at the War Memorial for the last time in uniform, as a humble tribute to those who laid down their lives in the line of duty. After the wreath laying, I was welcomed by friends, relatives and well-wishers. This is symbolic of my transition from uniform to civilian life," he said.Gen Chauhan's tenure was to end on September 30 last year, but he was given an extension.He had retired from service in May 2021 in the rank of lieutenant general, but assumed the rank of a four-star General after taking charge as India's second Chief of Defence Staff.Gen Chauhan was the Director General of Military Operations (DGMO) when Indian fighter jets pounded a Jaish-e-Mohammad terrorist training camp deep inside Pakistan's Balakot in February 2019. He was known to have provided key inputs for the operation.Born on May 18, 1961, Gen Chauhan was commissioned into the 11 Gorkha Rifles of the Indian Army in 1981.In his distinguished career, Gen Chauhan held several command, staff and instrumental appointments and had extensive experience in counter-insurgency operations in Jammu and Kashmir and Northeast India.The officer is an alumnus of the National Defence Academy, Khadakwasla, and the Indian Military Academy, Dehradun.In the rank of Maj General, the officer had commanded an Infantry Division in the critical Baramulla sector in the Northern Command.Later, he commanded a corps in the Northeast and subsequently went on to become the General Officer Commanding-in-Chief of the Eastern Command.Gen Chauhan was awarded with the Param Vishisht Seva Medal, Uttam Yudh Seva Medal, Ati Vishisht Seva Medal, Sena Medal and Vishisht Seva Medal for his exemplary services to the Indian Army.
One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.
LinkedIn cofounder Reid Hoffman believes the AI chatbot gold rush is over, shifting focus to AI-powered medicine as the next massive opportunity. He highlights healthcare's larger market and the potential for AI to accelerate drug discovery, creating lucrative monopolies through patent-protected innovations. Hoffman also noted that the medical field is not a winner-take-all market, allowing for multiple successful players.
The two groups pelted stones at each other and also used sticks and axes in the fight, creating panic in the village.